Sermorelin for CrossFit and High-Volume Training: A Structured Recovery Protocol

What Is Sermorelin and Why Do CrossFit Athletes Use It?

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and triggers a pulsatile release of growth hormone (GH), which in turn drives hepatic insulin-like growth factor-1 (IGF-1) synthesis. Unlike exogenous recombinant human GH (rhGH), sermorelin preserves the natural feedback loop: somatostatin still limits secretion, which reduces the risk of supraphysiologic GH levels.

CrossFit-style training combines weightlifting, gymnastics, and metabolic conditioning in sessions that can exceed 60 minutes at high intensity. Accumulated training stress generates significant muscle protein breakdown and systemic inflammation. GH plays a documented role in skeletal muscle repair and lipolysis, making GHRH stimulation a logical target for recovery optimization.

The GH-IGF-1 Axis in High-Intensity Training

Resistance and high-intensity interval training acutely raise GH. A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that GH pulse amplitude correlates with training volume and that chronic high-volume athletes show blunted GH recovery between sessions relative to controls [1]. This blunting is where sermorelin's mechanism is most relevant: it re-amplifies each nighttime GH pulse rather than suppressing the axis.

IGF-1 is the downstream biomarker most reliably tied to muscle protein synthesis and satellite cell activation. In a randomized, double-blind, placebo-controlled trial by Corpas et al. (N=22 older men), GHRH administration for 6 months increased mean IGF-1 by approximately 33% above baseline [2]. Baseline IGF-1 in athletes should ideally sit between 150 to 300 ng/mL before adding any GH-axis peptide.

Why Not Use Exogenous rhGH Instead?

Exogenous rhGH suppresses endogenous GHRH and somatostatin signaling over time. A 2004 review in Annals of Internal Medicine found that rhGH in healthy adults modestly reduced fat mass but did not improve muscle strength, and adverse events (edema, arthralgias, carpal tunnel) occurred in up to 30 to 40% of participants [3]. Sermorelin's physiologic pulse preservation makes it a lower-risk entry point for athletes not diagnosed with GH deficiency.

How to Structure a Sermorelin Protocol for CrossFit Recovery

Dosing Range and Titration

Start at 200 mcg per injection. Most practitioners titrate to 300 to 500 mcg based on IGF-1 response at week 8. Doses above 500 mcg per night rarely produce proportionally greater IGF-1 elevation and increase the risk of injection-site reactions, flushing, and transient somnolence.

Pediatric data from Geref (sermorelin acetate for injection) trials used weight-based dosing of approximately 0.03 mg/kg/day, but adult athletic protocols in the observational literature converge on a flat dose of 200 to 500 mcg rather than weight-adjusted dosing. The flat-dose convention reflects pituitary saturation kinetics: GHRH receptor occupancy plateaus before the dose climbs proportionally to body weight in healthy adults.

Injection Route and Technique

Subcutaneous injection into the periumbilical abdominal fat, outer thigh, or lateral hip is standard. Use a 28 to 31 gauge, 0.5-inch insulin syringe. Rotate sites with each injection to prevent lipohypertrophy.

Reconstitution: lyophilized sermorelin powder is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol preserved). A common reconstitution is 2 mg powder into 2 mL bacteriostatic water, yielding 1,000 mcg/mL. Store the vial at 2 to 8°C after reconstitution; use within 28 days.

Timing Around Training and Meals

Inject 30 to 60 minutes before sleep, at least 2 to 3 hours after the last meal. Elevated insulin from a recent carbohydrate-containing meal blunts GH secretion via somatostatin upregulation. A 2015 study in Endocrinology confirmed that postprandial hyperinsulinemia suppresses GHRH-stimulated GH release by approximately 40% [4]. Athletes with evening training sessions should eat their post-workout meal immediately after training, then allow 2 to 3 hours before the bedtime sermorelin injection.

On heavy training days (e.g., competition-prep cycles with two-a-day sessions), the bedtime injection may be moved 15 to 30 minutes earlier if the athlete will sleep early. The injection window should not shift to daytime, because endogenous GH pulsatility is strongly sleep-phase-dependent [5].

Cycle Length and Off-Periods

Run sermorelin for 12 to 24 consecutive weeks, then take a 4-week break before re-evaluating. IGF-1 returns to near-baseline within 4 to 6 weeks of stopping, consistent with the peptide's short half-life (approximately 10 to 20 minutes) and the lack of pituitary axis suppression. Unlike anabolic steroids, sermorelin does not require a pituitary recovery period, but cycling off preserves receptor sensitivity.

A commonly used programming structure for CrossFit athletes:

• Weeks 1 to 12: 300 mcg nightly, 5 nights/week (Mon, Fri)
• Lab check at week 8 to 10: adjust dose to 400 to 500 mcg if IGF-1 has not risen at least 30 ng/mL above baseline
• Weeks 13 to 16: optional extension at 200 mcg (maintenance dose), or 4-week washout
• Re-start after washout: repeat baseline IGF-1 before initiating next cycle

Lab Monitoring Protocol

Baseline Panel (Before First Injection)

| Lab | Rationale | |---|---| | Serum IGF-1 | Primary efficacy endpoint; also screens for pre-existing GH excess | | Fasting glucose and HbA1c | GH raises insulin resistance transiently; monitor in pre-diabetic athletes | | TSH and free T4 | Hypothyroidism blunts GH response; sermorelin is ineffective if TSH is high | | Comprehensive metabolic panel | Hepatic IGF-1 synthesis requires normal liver function | | Total and free testosterone (men) | GH and testosterone share anabolic combination; know your baseline | | Estradiol (women) | Estrogen modulates GH pulse amplitude; useful in female athletes | | Complete blood count | Screens for contraindicated conditions |

Monitoring at Weeks 8 to 12

Recheck serum IGF-1 at week 8 to 12. An IGF-1 increase of 30 to 80 ng/mL above baseline is a reasonable therapeutic target. If IGF-1 exceeds 350 ng/mL, reduce the dose by 100 mcg and recheck in 4 weeks. Persistent IGF-1 above 400 ng/mL warrants discontinuation and physician review.

Recheck fasting glucose at week 12 if baseline was in the impaired fasting glucose range (100 to 125 mg/dL). A 12-month RCT of GHRH analogs (N=89) published in JCEM found a statistically significant but clinically modest rise in fasting insulin without a change in HbA1c at doses below 1 mg/day [6].

Final End-of-Cycle Labs

Before the washout, collect a final IGF-1 and fasting metabolic panel. Document the peak IGF-1 achieved. This creates a reference point for future cycles and informs dose adjustment.

Expected Timeline of Outcomes in CrossFit Athletes

Weeks 1 to 3: Sleep Architecture Improvements

The first reported benefit is deeper, more restorative sleep. GH is secreted predominantly during slow-wave (stage 3) sleep. A double-blind crossover trial (N=16) showed that GHRH administration before sleep increased slow-wave sleep duration by a mean of 20 minutes compared to placebo [5]. CrossFit athletes typically notice they feel less groggy after training sessions and that heart rate variability (HRV) scores improve within the first 2 to 4 weeks.

Weeks 4 to 8: Soft Tissue and Joint Recovery

Collagen synthesis is GH-dependent. Athletes commonly report reduced tendon stiffness and faster resolution of DOMS (delayed-onset muscle soreness) during weeks 4 to 8. While no RCT has specifically measured sermorelin's effect on DOMS in CrossFit athletes, IGF-1 is a well-established driver of satellite cell proliferation and myofibrillar protein synthesis [7].

HealthRX CrossFit Recovery Response Framework

| Week | Primary Outcome | Monitoring Action | |---|---|---| | 1 to 3 | Sleep quality, HRV improvement | Track HRV nightly (wearable device) | | 4 to 8 | DOMS reduction, joint recovery | Subjective RPE log, tendon pain scales | | 8 to 12 | IGF-1 rise, lean mass retention | Lab recheck; body composition scan (DEXA) | | 12 to 24 | Body composition, strength metrics | Repeat DEXA, 1RM testing |

Weeks 8 to 16: Body Composition Shifts

GH promotes lipolysis through hormone-sensitive lipase activation and antagonizes insulin-mediated glucose uptake in adipocytes. In the Corpas GHRH trial, 6 months of treatment reduced mean body fat percentage by approximately 3% while lean mass was preserved [2]. For CrossFit athletes whose body composition is already lean, the more meaningful outcome is lean mass maintenance during a high-volume training block rather than dramatic fat loss.

Expect DEXA-measurable changes no earlier than week 10 to 12. Body weight on a scale may not shift significantly because fat loss and lean mass gains can offset each other.

Sermorelin in Female CrossFit Athletes

Women secrete GH in higher-amplitude pulses than age-matched men, partly because estrogen amplifies pituitary GH release. Post-menopausal women show reduced GH pulsatility, making them more responsive to sermorelin than their premenopausal counterparts. Premenopausal athletes at high training volumes can still benefit, particularly if IGF-1 is below 150 ng/mL at baseline.

Oral estrogen reduces hepatic IGF-1 production by the first-pass effect, so women on oral estrogen-containing contraceptives may show a blunted IGF-1 response to the same sermorelin dose. Transdermal estrogen does not carry this hepatic first-pass penalty. The Endocrine Society clinical practice guideline on GH deficiency notes that "GH requirements in women receiving oral estrogen are substantially higher" [8]. Practitioners managing female athletes on oral contraceptives should start at 300 mcg and may need to reach 500 mcg to achieve equivalent IGF-1 increments.

Luteal phase GH pulsatility is reduced relative to the follicular phase. Tracking IGF-1 at a consistent menstrual cycle phase (days 3 to 7) improves result reproducibility.

Sermorelin Stacking Considerations for CrossFit

With CJC-1295 (No DAC)

CJC-1295 without drug affinity complex (DAC) is a modified GHRH fragment with a half-life of approximately 30 minutes. Stacking it with sermorelin is common in practitioner circles but lacks RCT support specific to athletes. The mechanistic rationale is that CJC-1295 (no DAC) provides a slightly extended receptor occupation versus sermorelin's rapid clearance. Doses in this combination are typically reduced: 100 to 150 mcg of each peptide rather than 300 to 500 mcg of sermorelin alone. This combination should be considered experimental at the current evidence level.

With Ipamorelin (GHRP)

Ipamorelin is a growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors (GHSR-1a) rather than GHRH receptors. Combining a GHRH analog (sermorelin) with a GHRP (ipamorelin) produces a synergistic GH pulse by acting on two independent receptor systems simultaneously. A preclinical study published by Jiménez-Reina et al. Documented additive GH secretion when GHRH and ghrelin agonists were co-administered [9].

A common starting combination for CrossFit athletes: sermorelin 200 mcg plus ipamorelin 150 to 200 mcg, co-injected subcutaneously 30 to 60 minutes before sleep. This stack is practitioner-level observational experience, not RCT-supported in athletic populations.

Ipamorelin does not significantly raise cortisol or prolactin, which distinguishes it from older GHRPs like GHRP-2 and GHRP-6. This is a meaningful consideration for athletes already under hypothalamic-pituitary-adrenal stress from high training volumes.

With Testosterone Replacement Therapy (TRT)

Male athletes on TRT who add sermorelin often report amplified lean mass gains relative to either agent alone. Testosterone increases GH receptor expression in peripheral tissues and augments IGF-1 signaling. There is no pharmacokinetic interaction that changes sermorelin dosing when co-administered with TRT, but IGF-1 targets should be interpreted in the context of testosterone levels, as testosterone itself raises IGF-1 modestly.

Safety, Contraindications, and Side Effects

Sermorelin's safety profile in adults is well-characterized from its Geref clinical program. Common side effects include transient facial flushing (approximately 17% of patients), injection-site pain or redness, and mild somnolence [10]. These are generally dose-dependent and resolve within the first 2 to 4 weeks of use.

Absolute contraindications:

• Active or suspected malignancy (IGF-1 may be mitogenic in tumor cells)
• Pregnancy or breastfeeding
• Known hypersensitivity to sermorelin or GHRH

Relative contraindications:

• Untreated hypothyroidism (TSH should be below 4.0 mIU/L before starting)
• Active sleep apnea (GH worsens upper airway tone transiently)
• Uncontrolled type 2 diabetes (GH worsens insulin resistance)

Athletes using high-dose NSAIDs chronically should know that prostaglandin inhibition may blunt GH secretion and reduce sermorelin efficacy. A single bedtime dose of a COX inhibitor taken for post-workout analgesia is unlikely to be clinically significant, but daily NSAID use may attenuate the IGF-1 response.

The Endocrine Society's position statement on growth hormone use in sport explicitly states that "any use of GH or GH secretagogues for athletic performance enhancement in individuals without a documented GH deficiency falls outside approved indications and is banned by WADA" [8]. CrossFit athletes competing at sanctioned events should be aware that WADA prohibits GHRH analogs including sermorelin under the Peptide Hormones, Growth Factors, and Related Substances class (S2). A positive test at sanctioned competition carries significant competitive consequences.

Practical Injection Checklist for Athletes

1. Eat your last meal at least 2 to 3 hours before injection.
2. Draw up the correct volume into an insulin syringe (e.g., 0.3 mL for 300 mcg from a 1,000 mcg/mL solution).
3. Clean the injection site with an alcohol swab; allow it to dry for 10 seconds.
4. Pinch the skin and insert at 45 to 90 degrees depending on fat layer thickness.
5. Inject slowly over 5 to 10 seconds; do not aspirate for subcutaneous injections.
6. Apply light pressure to the site after withdrawal; do not rub.
7. Log the injection site, dose, and time in a training/peptide journal.
8. Refrigerate the reconstituted vial immediately after use.